HOUSTON--(BUSINESS WIRE)--July 17, 2006--Endovasc Inc. (OTCBB: EVSC - News), cites positive market conditions for its leading drug candidate, Liprostin, for the treatment of intermittent claudication, a symptom of peripheral arterial disease (PAD), leading up to the Company’s Phase IIIa trials for the drug. Management points to the failure of competing PAD drug treatments to meet their endpoints in recent clinical trials for its optimistic outlook for Liprostin.
